What Quest Diagnostics (DGX) Said on Its Q3 Earnings Call
Quest Diagnostics (DGX) reported Q3 operating income of $479M, up from $386M YoY. Adjusted EPS rose 15.4% to $3.00. The company expects full-year 2026 revenue of $12.065B-$12.105B. Quest plans to acquire select assets from a health system in the Northeastern U.S. and launched consumer health services via Apple Health app. Management addressed PAMA concerns, estimating a 1% revenue impact in 2027.
How this was made

The 30-second read
Why it matters
The earnings beat and guidance raise expectations for the diagnostics market, potentially boosting related stocks.
Market read
First report of Q3 numbers and upgraded guidance for a large-cap healthcare company; likely to move DGX and peers.
What to watch
Potential PAMA regulatory impact and cybersecurity incident could temper upside.
Background
Quest Diagnostics (NYSE:DGX) disclosed Q3 operating results and raised its 2026 outlook, including revenue, EPS, cash flow, and capital spending expectations.
Ticker impact
Quest Diagnostics reported Q3 results and raised full-year 2026 revenue and EPS guidance.
likely upward pressure as investors price in higher revenue and earnings outlook
Guidance increase of 9.3‑9.7% revenue growth and EPS $10.21‑$10.31 exceeds prior expectations, supporting a bullish reaction.
Market effects
Positive earnings may lift broader healthcare diagnostics sector.
U.S. healthcare stocks could see modest gains.
Limited to U.S. markets; no immediate global ripple.
Counterpoint
If guidance proves unsustainable, a pullback could follow.
Key entities
- companyQuest Diagnostics
Provider of diagnostic information services.


